Navigation Links
Karmanos Cancer Institute Researchers Present Breast Cancer Advancements at Conference
Date:4/20/2009

Abstract # 2905

DENVER, April 20 /PRNewswire-USNewswire/ -- Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit today presented data at the American Association for Cancer Research's 100th Annual Meeting 2009 that represents significant research advancements in the treatment of the most aggressive forms of invasive breast cancer.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSLOGO)

Karmanos researchers discovered that when an FDA-approved cancer treatment typically used to treat cutaneous T-cell lymphoma was administered before a novel experimental antitumor agent -- which works best in breast cancers expressing the estrogen receptor (ER) -- estrogen receptors were reinstated in receptor-negative breast cancer cells so that treatment was also effective in fighting the difficult to treat ER-negative disease.

Research was supervised by Angelika Burger, Ph.D., director of the Translational Research Laboratory at the Karmanos Cancer Institute and professor of Pharmacology at Wayne State University in Detroit. Karri Stark, a doctoral candidate with Wayne State University's School of Medicine, presented the findings.

Researchers have paired vorinostat, known by its pharmaceutical name Zolinza(R), with Aminoflavone Prodrug (also known as AFP464) and found that AFP464 and vorinostat work together to inhibit the growth of triple-negative breast cancer cells. "Triple-negative" refers to breast cancer cells that have no estrogen, progesterone or HER2 receptors needed for currently-available, targeted anticancer therapies to work effectively.

AFP464 is now in Phase I clinical trials at the Karmanos Cancer Institute in Detroit, the Mayo Clinic in Minnesota, and other cancer research centers in Paris and Brussels in Europe.

Dr. Burger says the findings offer particular hope to those women battling triple-negative breast cancer.

"We could now find a way to treat every kind of invasive, metastatic breast cancer, the ER-positive and ER-negative types with AFP464," she said. "The synergism is very impressive. We always knew vorinostat can reprogram the expression of cancer cells."

AFP464 has been in Phase I clinical trial for the last year and a half, where doses were given to patients with solid tumors. Dr. Burger says the next step is to take the anti-cancer agent to the second phase, where researchers administer to triple-negative breast cancer patients the drug alone or in combination with vorinostat. She expects that to occur in the next year and said that Karmanos could host one of those second-phase trials.

"We are currently conducting animal experiments with the single agents and the drug combination," Dr. Burger said. "Triple-negative breast cancers might respond against that drug (AFP464)."

Triple-negative breast cancer afflicts mostly young women under the age of 40 and is more prevalent in the African-American community. About 182,460 women in the United States were diagnosed with invasive breast cancer in 2008 and about 40,480 will die from the disease, according to the American Cancer Society. Dr. Burger said that about 14 percent to 18 percent of breast cancer cases are triple-negative.

She expects that this research could translate to real-world applications in the next five years.

"These are targeted agents that are being tested," Dr. Burger said. "Having a drug available to treat triple-negative breast cancer would be a major step in fighting this disease."

Located in mid-town Detroit, MI, the Barbara Ann Karmanos Cancer Institute is one of 40 National Cancer Institute-designated comprehensive cancer centers in the United States. Caring for more than 6,000 new patients annually on a budget of $216 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, the Karmanos Cancer Institute is among the nation's best cancer centers. Through the commitment of 1,000 staff, including nearly 300 faculty members, and supported by thousands of volunteer and financial donors, the Institute strives to prevent, detect and eradicate all forms of cancer. For more information call 1-800-KARMANOS or go to www.karmanos.org.


'/>"/>
SOURCE Karmanos Cancer Institute
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. DNA Vaccine Developed at the Karmanos Cancer Institute Fights HER2-Positive Cancers
2. Karmanos Doctors Urge Increased Screening for Previously Treated Lung Cancer Patients, Especially Young Women
3. Karmanos Cancer Institute Researchers Show Phase I Immunotherapy with Armed T Cells Improve Overall Survival of Metastatic Breast Cancer Patients
4. Karmanos Cancer Institute Research Supports Role of Inflammation to Determine Lung Cancer Risk, Particularly in African-American Women
5. Karmanos Researchers Study the Impact of Galectin-3 on Breast Cancer Disparity in Caucasian and Asian Women
6. Karmanos Researchers Find Non-Toxic Agents Added to Conventional Chemotherapy Decrease Survival of Colon Cancer Cells
7. Muscadine Grape Skin Dietary Supplement Protects against Cancer Therapy Radiation Side Effects
8. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
9. New Australian Drug Holds Hope of Major Breakthrough in Treating Terminal Blood Cancers
10. Genetic Source of Rare Childhood Cancer Found; Gene is Implicated in Other Cancers
11. Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):